SCHEMBL4219709

SCHEMBL4219709

O=C(OCc1ccccc1)C(O)Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
LTA4H P09960 1/20 0.54
LAP3 P28838 1/20 0.54
TDP1 Q9NUW8 2/20 0.53
MAPK1 P28482 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A3 Q01959 1/20 0.53
KMT2A Q03164 1/20 0.53
CTRB1 P17538 2/20 0.51
LMNA P02545 2/20 0.49
HCAR2 Q8TDS4 1/20 0.49
CYP1A2 P05177 1/20 0.48
CTSB P07858 1/20 0.47
SLC15A1 P46059 1/20 0.47
SRR Q9GZT4 1/20 0.46
ABCB1 P08183 1/20 0.46
TACR1 P25103 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL262278 1.00 ALDH1A1 (0.55) ALDH1A1LTA4HLAP3TDP1MAPK1
SCHEMBL7046944 1.00 ALDH1A1 (0.55) ALDH1A1LTA4HLAP3TDP1MAPK1
SCHEMBL19088598 0.93 LMNA (0.56) ALDH1A1LTA4HLAP3TDP1MAPK1
SCHEMBL18256456 0.90 LTA4H (0.50) ALDH1A1LTA4HLAP3TDP1MAPK1
SCHEMBL7228873 0.90 PPARG (0.52) ALDH1A1LTA4HLAP3TDP1MAPK1
SCHEMBL23279460 0.90 PPARG (0.52) ALDH1A1LTA4HLAP3TDP1MAPK1
SCHEMBL19088471 0.90 LTA4H (0.50) ALDH1A1LTA4HLAP3TDP1MAPK1
SCHEMBL18407490 0.90 ALDH1A1 (0.50) ALDH1A1LTA4HLAP3TDP1MAPK1
SCHEMBL22502779 0.90 ALDH1A1 (0.50) ALDH1A1LTA4HLAP3TDP1MAPK1
SCHEMBL8953583 0.90 LTA4H (0.53) ALDH1A1LTA4HLAP3TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117402206-A Method for preserving and stabilizing proteins for use in the development of hygienic preparations, pharmaceutical and cosmetic industries 萨尼雷德有限公司 2024-01-16 CN claimed
EP-4595978-A1 ANTI-CD33 ANTIBODY AND ANTI-CD33 ANTIBODY-DRUG CONJUGATE AND USE THEREOF SystImmune, Inc. (US) 2025-08-06 EP disclosed
US-12286455-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2025-04-29 US disclosed
CN-117402206-A Method for preserving and stabilizing proteins for use in the development of hygienic preparations, pharmaceutical and cosmetic industries 萨尼雷德有限公司 2024-01-16 CN disclosed
US-20230226207-A1 Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof SYSTIMMUNE, INC. 2023-07-20 US disclosed
US-20230226207-A1 Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof SYSTIMMUNE, INC. 2023-07-20 US disclosed
CN-114891070-A Anthelmintic depsipeptide compounds 勃林格殷格翰动物保健美国公司 2022-08-12 CN disclosed
US-11382949-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2022-07-12 US disclosed
CN-107835818-B Anthelmintic depsipeptide compounds 勃林格殷格翰动物保健美国公司 2022-04-29 CN disclosed
EP-3922639-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2021-12-15 EP disclosed
US-5142048-A Enzyme inhibitor; carbamoyl group-containing acids FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1992-08-25 US disclosed
US-4931591-A Novel 5-amino-4-hydroxyvaleryl derivatives CIBA-GEIGY CORPORATION (US) 1990-06-05 US disclosed
US-4921855-A New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-05-01 US disclosed
EP-0355331-A2 Poly(aminoalkyl)aminocarbonyl aminoacyl aminodiol amino acid derivatives as anti-hypertensive agents G.D. Searle & Co. (US) 1990-02-28 EP disclosed
US-4902706-A Aminoalkylaminocarbonyl aminodiol amino acid derivatives as antihypertensive agents G. D. SEARLE & CO. (US) 1990-02-20 US disclosed
WO-1990000052-A1 POLY(AMINOALKYL)AMINOCARBONYL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS G.D. SEARLE & CO. (US) 1990-01-11 WO disclosed
EP-0349922-A2 Aminoalkylaminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents G.D. Searle & Co. (US) 1990-01-10 EP disclosed
EP-0300189-A2 New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-01-25 EP disclosed
CN-1030411-A New amino acid derivatives, its preparation method and contain its pharmaceutical composition FUJISAWA PHARMACEUTICAL CO (JP) 1989-01-18 CN disclosed
US-4727060-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1988-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11382949-B2 Anthelmintic depsipeptide compounds ENPP2, ROCK2, RRP12 ALDH1A1 3183/4885LTA4H 1542/4885LAP3 3416/4885
US-20230226207-A1 Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof SLC7A1, CD44, DCLRE1A ALDH1A1 2318/4885LTA4H 2121/4885LAP3 2575/4885
US-12286455-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP ALDH1A1 3037/4885LTA4H 327/4885LAP3 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.